Summit Therapeutics Inc. (NASDAQ: SMMT) is a Healthcare company (Biotechnology) with a market capitalization of $8.5B. The Maz Rating grades it against the other companies in its sector.
Summit Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $10.67, Summit Therapeutics Inc. trades at 15.0x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -138.8%, return on invested capital of -145.8% and a free cash flow yield of -6.2%. On the balance sheet: a debt-to-equity ratio of 0.04 and a current ratio of 5.99. Over the past 52 weeks the share price ranged from $10.53 to $29.23, with a beta of -1.24.
Summit Therapeutics Inc. does not currently pay a dividend.
23 Wall Street analyst ratings cover the stock: 15 Buy and 8 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Summit Therapeutics Inc. (SMMT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 5.14% / 30% · Interest income / Revenue 649900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.14% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 649900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.14% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 649900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.72% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 92.6% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 649900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 90.9% / 33.33% · (Cash+Recv) / Total Assets 90.9% / 33.33% · Interest income / Revenue 649900000.0% / 5% | Fail |
No. As of September 2026, Summit Therapeutics Inc. (SMMT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Summit Therapeutics Inc. is over the AAOIFI limit on Interest income / Revenue.
About 649900000.0% of each dividend: Summit Therapeutics Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.